

CERTIFICATE OF EXPRESS MAIL

NUMBER EL611000881US

DATE OF DEPOSIT December 22, 2000

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Xiaodong Wong

Xuesong Liu

Group Art Unit: Unknown

Examiner: Unknown

Serial No.: Unknown

Atty. Dkt. No.: UTSD:546USD1

Filed: Herewith

For: DNA FRAGMENTATION FACTOR
INVOLVED IN APOPTOSIS

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Commissioner:

Please amend this application as follows:

In The Specification

At page 2, line 1, insert the following:

--This is a divisional of co-pending application Serial No. 09/061,702, filed April 16,
1998.--

In the Claims

Cancel claims 1-90 and 92-93, without prejudice or disclaimer.

Please add the following claims.

116. The peptide of claim 113, wherein the peptide is conjugated to a carrier molecule.

117. The peptide of claim 116, wherein the carrier molecule is selected from the group consisting of KLH and BSA.--

REMARKS

Claims 77-89 and 101-107 were prosecuted in the parent case, application Serial No. 09/061,702, which was allowed on July 12, 2000, but has not yet issued. In this divisional application, Applicants are prosecuting claims corresponding to Group I, as described in the Restriction Requirement dated June 23, 1999. Herein, claims 1-90 and 92-93 are cancelled. Claims 94-117 have been added; these added claims correspond to claims originally constituting Group I and to claims within the scope of Group I. Support for the added claims can be found in the Specification at least at page 16, lines 1-11; page 23, lines 1-4 and 27-28; and in the originally filed claims, which form part of this application's written description. Thus, the active claims in this case are claims 91 and 94-117. A copy of the pending claims can be found in Appendix A.

The specification has been amended to recite the relationship with the parent case.

Also transmitted herewith is a diskette containing the computer readable form of those sequences in the specification, a verified statement in accordance with the sequence rules, and a separate paper copy of the sequence listing. Applicants are submitting a new version of the sequence listing filed in the parent application for the sole reason of complying with the form requirements according to 37 C.F.R. §1.823. No new matter has been added to the application.

[illegible]

100

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3081

Date: December 22, 2000